This study provides insights into the epigenetic role of SMYD3 as an oncogene in HPV-negative HNSCC and supports SMYD3 as a rational therapeutic target in HPV-negative HNSCC. The gene discussed is SMYD3; the disease is head and neck squamous cell carcinoma.